The Book of PeptidesThe Book of Peptidessemaglutide / tirzepatide / retatrutide + BPC-157
The signature tolerance pairing of the GLP-1 era: BPC-157 run alongside semaglutide, tirzepatide or retatrutide in the hope of blunting the nausea, reflux and gut distress that dominate every GLP-1 trial's side-effect table — a gut-lining "protectant" under the compound doing the real work.
The GLP-1 drug does the metabolic work and causes the GI symptoms; BPC-157 — reported in rodent studies, almost all from one research group, to protect the gut lining against contact injury — is layered underneath on the theory that a tougher, faster-healing lining rides it out, taken orally for direct contact.
The published per-compound doses, timing, cycle length, the mechanism sources give for why it's combined, and the harm-reduction notes — the parts that took the most research to get right — are part of membership.